Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Affimed NV's Free Cash Flow for the
three
months ended in Sep. 2024 was $-12.36 Mil. Affimed NV's Revenue for the
three
months ended in Sep. 2024 was $0.17 Mil. Therefore, Affimed NV's FCF Margin % for the quarter that ended in Sep. 2024 was -7,188.37%.
The historical rank and industry rank for Affimed NV's FCF Margin % or its related term are showing as below:
AFMDQ'
s FCF Margin % Range Over the Past 10 Years
Min: -8822.7 Med: 0 Max: 0
Current: -8822.7
AFMDQ's FCF Margin % is not ranked
in the Biotechnology industry.
Industry Median: -82.715
vs AFMDQ: -8822.70
Affimed NV FCF Margin % Related Terms
Affimed NV FCF Margin % Historical Data
* Premium members only.
The historical data trend for Affimed NV's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AFMDQ vs SYRS, BTAX, TRVN: FCF Margin % Comparison
For the Biotechnology subindustry, Affimed NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Affimed NV FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Affimed NV's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Affimed NV's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Affimed NV (AFMDQ) has a FCF Margin % of -7,188.37% as of Sep. 2024. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Affimed NV and its competitors.
Is Affimed NV's FCF Margin % too high?
Affimed NV's current FCF Margin % is -7,188.37%. Overall, Affimed NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Affimed NV's FCF Margin % compare to SYRS and BTAX?
Affimed NV's FCF Margin % of -7,188.37% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Affimed NV and its competitors. Affimed NV's current FCF Margin % is -7,188.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Affimed NV stock overvalued right now?
Affimed NV (AFMDQ) has a current FCF Margin % of -7,188.37%. The current FCF Margin % is -7,188.37%. Affimed NV's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Affimed NV (AFMDQ), the current FCF Margin % is -7,188.37% as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
16GF Score
Get the complete analysis for AFMDQ
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AFMDQ has been successfully added to your 
